Eflornithine for Hirsutism and Hypertrichosis

Eflornithine for Hirsutism and Hypertrichosis - A Snapshot

- Eflornithine is a topical medication recognised for its effectiveness in reducing unwanted facial hair growth. It works by inhibiting the enzyme ornithine decarboxylase, which plays a key role in hair growth.

- In the United States, Eflornithine is available under the brand name Vaniqa as a 13.9% cream. However, in Australia, whilst it was commercially available from the early 2000’s to 2018, it is no longer available and needs to be compounded.

- In Australia, Eflornithine is commonly compounded as a 13.9% cream, which is the standard concentration found in the commercially available product Vaniqa.

- It is commonly used in patients with hirsutism secondary to polycystic ovarian syndrome.

- Patients are generally advised to apply Eflornithine cream twice daily, with at least eight hours between applications. It should be applied to clean, dry skin and rubbed in thoroughly. Continuous use is essential for maintaining its hair growth reduction effects.

- Uncommon side effects of Eflornithine include mild skin irritation, redness, and a burning sensation at the application site. It is important to avoid contact with the eyes and mucous membranes.